Lundbeck to spend billions on global sales offensive  

Danish pharma company Lundbeck will spend DKK 5 billion over 5 years to globally market its antidepressant Lexapro

Over the next 5 years, Danish pharmaceutical company H. Lundbeck A/S will be investing more than DKK 1 billion (USD 130 million) each year to globally market its antidepressant drug Lexapro (escitalopram), reports Berlingske Tidende today. Lundbeck has just entered into an agreement with Abbott Laboratories to market, sell and distribute Lexapro in all Latin American markets. The follow-up target is Asia and Lundbeck expects to have a marketing alliance in place within months. The marketing initiative is described as one of largest ever undertaken by a Danish company, and if successful will make Lundbeck one of Denmark's largest concerns. According to Morgan Stanley in London, Lundbeck's expansion plans are "an important step in the right direction".


Lexapro, a second generation antidepressant, belongs to the class of selective serotonin reuptake inhibitors (SSRIs) for the treatment of depression and panic disorders. Lexapro is also sold under the trade name Cipralex in many other countries throughout the world. Lexapro has been approved in the United States of America, Mexico, United Kingdom, Sweden, Switzerland, France, Denmark, Lithuania, Belgium, Ireland, Iceland, Luxembourg, Norway, and Austria. Lundbeck is currently awaiting regulatory approval for Lexapro in a number of other countries.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×